Updated: AstraZeneca jumps deeper into cell therapy 2.0 space with $320M biotech M&A
Right from the start, the execs at Neogene had some lofty goals in mind when they decided to try their hand at a cell therapy that could tackle solid tumors.
Its founders have helped hone a new approach that would pack in multiple neoantigen targets to create a personalized TCR treatment that would not just make the leap from blood to solid tumors, but do it with durability. And they managed to make their way rapidly to the clinic, unveiling their first Phase I program for advanced tumors just last May.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.